Full-Time

Sr. Director of Software Quality

Confirmed live in the last 24 hours

Veracyte

Veracyte

501-1,000 employees

Develops genomic tests for cancer diagnosis

Biotechnology
Healthcare

Compensation Overview

$200k - $231kAnnually

+ Bonus + Incentives + Restricted Stock Units

Senior, Expert

Remote in USA + 2 more

More locations: San Bruno, CA, USA | San Diego, CA, USA

Hybrid position; remote work available for West Coast time zone candidates.

Category
QA & Testing
Automation Testing
Quality Assurance
Required Skills
Risk Management

You match the following Veracyte's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • 10+ years in software quality, with 5+ years in medical devices/diagnostics
  • Bachelor’s in computer science or related field (Master's preferred)
  • Deep knowledge of FDA regulations (21 CFR Part 820, Part 11) and ISO standards
  • Experience validating third-party applications in regulated environments
  • Expertise in: Test automation frameworks, API testing and integration validation, Risk management and compliance, SDLC methodologies, Cloud security validation, HIPAA compliance
  • Proven success leading 5+ person teams
  • Strong executive presence
  • Strategic thinking with tactical execution
  • Excellence in stakeholder management
  • Track record of developing top talent
  • Ability to travel once a quarter
Responsibilities
  • Lead software quality initiatives and build a world-class team
  • Architect and implement processes that ensure the integrity of diagnostic solutions
  • Oversee validation efforts across the technology ecosystem
  • Ensure quality is embedded throughout the product development lifecycle
  • Manage regulatory audits and compliance documentation
Desired Qualifications
  • Cancer diagnostics/precision medicine background
  • ASQ certification
  • Experience with: Clinical laboratory operations, Third-party healthcare software validation, GxP-regulated systems, Electronic health record integrations

Veracyte develops and sells advanced genomic tests for the early detection and diagnosis of various cancers. Their tests analyze genetic information from non-invasive samples, such as nasal swabs or tissue biopsies, to provide insights into the presence and progression of cancer. This information helps healthcare providers, including hospitals and clinics, make informed treatment decisions for their patients. Veracyte differentiates itself from competitors by focusing on non-invasive testing methods and continuously investing in research to expand its product offerings. The company's goal is to improve cancer diagnosis accuracy, leading to better patient outcomes and more efficient healthcare resource use.

Company Size

501-1,000

Company Stage

IPO

Total Funding

$69.4M

Headquarters

San Francisco, California

Founded

2008

Simplify Jobs

Simplify's Take

What believers are saying

  • Increasing demand for personalized medicine boosts genomic diagnostics growth.
  • AI integration enhances accuracy and speed of Veracyte's cancer diagnostics.
  • Regulatory support is improving for genomic testing, streamlining approvals.

What critics are saying

  • AI-based tests may have bias due to initial development on limited demographics.
  • MRD assay launch in 2026 may face reimbursement challenges with commercial payers.
  • ClearLab's 2026 launch may encounter significant market competition.

What makes Veracyte unique

  • Veracyte specializes in non-invasive genomic tests for early cancer detection.
  • The Decipher Prostate genomic classifier aids in prostate cancer prognosis.
  • Veracyte's nasal swab test improves early lung cancer risk assessment.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Stock Options

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

-2%
MLO Online
Feb 17th, 2025
New Data at ASCO demonstrates the performance and clinical utility of Veracyte's Decipher Prostate and Decipher Bladder tests

Veracyte, Inc. announced that new data presented at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) demonstrate the performance and clinical utility of its Decipher Prostate and Decipher Bladder tests to help guide treatment for patients with prostate and bladder cancer.

MarketBeat
Dec 21st, 2024
HighTower Advisors LLC Makes New Investment in Veracyte, Inc. (NASDAQ:VCYT)

HighTower Advisors LLC makes new investment in Veracyte, Inc. (NASDAQ:VCYT).

Inside Precision Medicine
Oct 3rd, 2024
Veracyte's RNA Genetic Test Predicts Black Men's Aggressive Prostate Cancer

That's why Veracyte is testing their Decipher Prostate Genomic Classifier, an AI-based transcriptome genetic test that was developed using primarily White American males, on Black African American males to see if it offers clinicians an improvement over clinical factors alone in guiding prostate cancer treatment decisions.

Investing.com
Sep 4th, 2024
Veracyte expands board with two new members

SOUTH SAN FRANCISCO, Calif. - Veracyte, Inc. (NASDAQ:VCYT), a global cancer diagnostics company, announced today the addition of Brent Shafer and Tom Miller, Ph.D., to its board of directors, effective immediately.

Stock Titan
Sep 4th, 2024
Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors

SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced the appointment of Brent Shafer and Tom Miller, Ph.D., to its board of directors, effective immediately.